Your browser doesn't support javascript.
loading
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Basarab, Gregory S; Kern, Gunther H; McNulty, John; Mueller, John P; Lawrence, Kenneth; Vishwanathan, Karthick; Alm, Richard A; Barvian, Kevin; Doig, Peter; Galullo, Vincent; Gardner, Humphrey; Gowravaram, Madhusudhan; Huband, Michael; Kimzey, Amy; Morningstar, Marshall; Kutschke, Amy; Lahiri, Sushmita D; Perros, Manos; Singh, Renu; Schuck, Virna J A; Tommasi, Ruben; Walkup, Grant; Newman, Joseph V.
Afiliação
  • Basarab GS; Department of Chemistry, Drug Discovery and Development Center, University of Cape Town, Rondebosch 7701, South Africa.
  • Kern GH; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • McNulty J; Shire Pharmaceuticals, 300 Shire Way, Lexington, MA 02421.
  • Mueller JP; Entasis Therapeutics, 35 Gatehouse Drive Suite E0, Waltham, MA 02415 USA.
  • Lawrence K; Entasis Therapeutics, 35 Gatehouse Drive Suite E0, Waltham, MA 02415 USA.
  • Vishwanathan K; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • Alm RA; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • Barvian K; Albany Molecular Research Inc., 26 Corporate Circle, Albany, NY 12203.
  • Doig P; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • Galullo V; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • Gardner H; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • Gowravaram M; Center for Drug Evaluation and Research, U.S. FDA, 10903 New Hampshire Avenue, Silver Spring, MD 20993.
  • Huband M; JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317.
  • Kimzey A; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • Morningstar M; Broad Institute, 415 Main St., Cambridge, MA 02142.
  • Kutschke A; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • Lahiri SD; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • Perros M; Shire Pharmaceuticals, 300 Shire Way, Lexington, MA 02421.
  • Singh R; Department of Chemistry, Drug Discovery and Development Center, University of Cape Town, Rondebosch 7701, South Africa.
  • Schuck VJ; Norvartis Pharmaceutical Corporation, Bldg. 335, Office 3104B, One Health Plaza, East Hanover, NJ 07936-1080.
  • Tommasi R; Shire Pharmaceuticals, 300 Shire Way, Lexington, MA 02421.
  • Walkup G; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
  • Newman JV; AstraZeneca R&D Boston, Infection iMed, 35 Gatehouse Dr. Waltham, MA 02415 USA.
Sci Rep ; 5: 11827, 2015 Jul 14.
Article em En | MEDLINE | ID: mdl-26168713
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Espiro / Barbitúricos / Gonorreia / Inibidores da Topoisomerase II / Antibacterianos Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Espiro / Barbitúricos / Gonorreia / Inibidores da Topoisomerase II / Antibacterianos Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article